Myositis - Pipeline Insight, 2021

DelveInsight’s, “Myositis - Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Myositis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Myositis Understanding
Myositis: Overview
The term “myositis” refers to a general inflammation or swelling of the muscle. Many people have experienced sore muscles after vigorous exercise, a condition that is temporary and improves with rest. Other conditions that can cause muscle weakness and pain include infection, muscle injury from medications, inherited diseases, electrolyte imbalances, and thyroid disease. More often, however, the term myositis is used to refer to a disease involving chronic inflammation of the muscles, often occurring together with other symptoms. This condition is also known as idiopathic inflammatory myopathy (IIM). The disease is highly variable and has been classified into a number of forms, including: Dermatomyositis (DM), Polymyositis (PM), Necrotizing myopathy (NM), Sporadic inclusion body myositis (sIBM), Juvenile forms of myositis (JM). Myositis is often difficult to diagnose, because many physicians are unfamiliar with the disease and its symptoms. A typical diagnosis process for myositis patients begins with a medical history and physical examination. It may also include blood tests, muscle and skin biopsies, and a variety of other diagnostic tests.

""Myositis - Pipeline Insight, 2021"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Myositis pipeline landscape is provided which includes the disease overview and Myositis treatment guidelines. The assessment part of the report embraces, in depth Myositis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myositis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Myositis R&D. The therapies under development are focused on novel approaches to treat/improve Myositis.

Myositis Emerging Drugs Chapters
This segment of the Myositis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Myositis Emerging Drugs
• Lenabasum: Corbus Pharmaceuticals
Lenabasum is a novel, oral, small molecule designed to provide an alternative to immunosuppressive treatments for inflammatory or fibrotic diseases. Lenabasum binds to and activates the cannabinoid receptor type 2 (CB2), which is preferentially expressed on activated immune cells, to resolve inflammation and limit fibrosis. Data from animal models and human clinical studies suggest that lenabasum can reduce expression of genes and proteins involved in inflammation and fibrosis. In clinical testing to date, lenabasum has acceptable safety and tolerability profiles.

• Belimumab: GlaxoSmithKline
Belimumab is a fully human monoclonal antibody that has been developed by GlaxoSmithKline/MedImmune for the treatment of autoimmune disorders. Currently, it is in Phase II stage of development to treat Myositis.
Further product details are provided in the report……..

Myositis: Therapeutic Assessment
This segment of the report provides insights about the different Myositis drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Myositis
There are approx. 15+ key companies which are developing the therapies for Myositis. The companies which have their Myositis drug candidates in the most advanced stage, i.e. phase III include, Corbus Pharmaceuticals.

• Phases
DelveInsight’s report covers around 15+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates
• Route of Administration
Myositis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Myositis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Myositis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myositis drugs.

Myositis Report Insights
• Myositis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Myositis Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Myositis drugs?
• How many Myositis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Myositis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Myositis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Myositis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• GlaxoSmithKline
• Corbus Pharmaceuticals
• Abcuro, Inc.
• Orphazyme
• Bristol-Myers Squibb
• Kezar Life Sciences, Inc.
• Viela Bio
• Paean Biotechnology Inc.
• Alexion Pharmaceuticals
• Janssen Biotech
• CSL Behring
• Pfizer
• Restem, LLC.
• Roche

Key Products
• Belimumab
• Lenabasum
• ABC008
• Abatacept
• KZR-616
• MEDI7734
• PN-101
• Ravulizumab
• tocilizumab
• PF-06823859
• Ustekinumab

Please Note: It will take 3-5 business days to complete the report upon order confirmation.

Executive Summary
Myositis: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Myositis – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
• Comparative Analysis
Lenabasum: Corbus Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
KZR-616: Kezar Life Sciences
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
ABC 008: Abcuro
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Myositis Key Companies
Myositis Key Products
Myositis- Unmet Needs
Myositis- Market Drivers and Barriers
Myositis- Future Perspectives and Conclusion
Myositis Analyst Views
Myositis Key Companies
Table 1 Total Products for Myositis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Figure 1 Total Products for Myositis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings